Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS31YW)

• Drug Name: YM-57158 Drug Info
• Synonyms: YM-158; 3-(4-tert-Butylthiazol-2-ylmethoxy)-N-[5-[3-(4-chlorophenylsulfonyl)propyl]-2-(1H-tetrazol-5-ylmethoxy)phenyl]benzamide monosodium salt monohydrate

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 5312140
  TTD Drug ID: DMS31YW

Molecule-Related Drug Atlas

Drug(s) Targeting Leukotriene CysLT1 receptor (CYSLTR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Montelukast	DMD157S	Allergic asthma	CA23.0	Approved	[2]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[3]
Pranlukast	DMYHDCA	Allergic rhinitis	CA08.0	Approved	[4]
Cinalukast	DMFIC0M	Asthma	CA23	Approved	[5]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[6]
BAY-X-7195	DM2XE80	Asthma	CA23	Phase 2	[7]
Masilukast	DMDTI0L	Asthma	CA23	Phase 2	[8]
LM-1507.NA	DMW6VA0	Asthma	CA23	Phase 2	[9]
Iralukast	DMQ3RWN	Asthma	CA23	Phase 2	[10]
CR-3465	DMT7L30	Allergy	4A80-4A85	Phase 1	[8]

Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[11]
Ridogrel	DMWH9CN	Acute myocardial infarction	BA41	Approved	[12]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[13]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[14]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[6]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[15]
TAK-128	DMHPEFS	Diabetic neuropathy	8C0Z	Phase 2	[16]
Ifetroban sodium	DMZP84Y	Thrombosis	DB61-GB90	Phase 2	[17]
Ifetroban	DMEV39E	Aspirin-induced asthma	CA23.20	Phase 2	[18]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukotriene CysLT1 receptor (CYSLTR1)	TTGKOY9	CLTR1_HUMAN	Modulator	[1]
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Modulator	[1]

References

• [1] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [2] Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94.
• [3] Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45.
• [4] Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203.
• [5] Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5.
• [6] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [7] The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85.
• [8] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [9] Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46.
• [10] Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8.
• [11] Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
• [12] Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
• [13] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [14] Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
• [15] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [16] ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [17] AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
• [18] Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
• [19] G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.